ArticleNature communications2020
Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing.
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed.
- A statistical physics approach to integrating multi-omics data for disease-module detection.Cell reports methods · 2025Article
- Unlocking biological insights from differentially expressed genes: Concepts, methods, and future perspectives.Journal of advanced research · 2025Review
- Drug Repurposing for Kala-Azar.Pharmaceutics · 2025Article
- VITALdb: to select the best viroinformatics tools for a desired virus or application.Briefings in bioinformatics · 2025Article
- NApy: efficient statistics in Python for large-scale heterogeneous data with enhanced support for missing data.GigaScience · 2025Article
- A graph neural network-based approach for predicting SARS-CoV-2-human protein interactions from multiview data.PloS one · 2025Article
- Exploration of drug repurposing for Mpox outbreaks targeting gene signatures and host-pathogen interactions.Scientific reports · 2024Article
- A comprehensive benchmark study of methods for identifying significantly perturbed subnetworks in cancer.Briefings in bioinformatics · 2024Article
- Drug Repurposing for COVID-19 by Constructing a Comorbidity Network with Central Nervous System Disorders.International journal of molecular sciences · 2024Article
- Drugst.One - a plug-and-play solution for online systems medicine and network-based drug repurposing.Nucleic acids research · 2024Article
- COVID-19 drug discovery and treatment options.Nature reviews. Microbiology · 2024Review
- TTD: Therapeutic Target Database describing target druggability information.Nucleic acids research · 2024Article
- Combination therapy synergism prediction for virus treatment using machine learning models.PloS one · 2024Article
- Emerging Treatment Approaches for COVID-19 Infection: A Critical Review.Current molecular medicine · 2024Review
- Maximizing Treatment Options for IBD through Drug Repurposing.Current pharmaceutical design · 2024Review
- The Local Anaesthetic Procaine Prodrugs ProcClusterInternational journal of molecular sciences · 2023Article
- Total network controllability analysis discovers explainable drugs for Covid-19 treatment.Biology direct · 2023Article
- Total network controllability analysis discovers explainable drugs for Covid-19 treatment.Research square · 2023Article
- Drugst.One - A plug-and-play solution for online systems medicine and network-based drug repurposing.ArXiv · 2023Article
- Systematic Guidelines for Effective Utilization of COVID-19 Databases in Genomic, Epidemiologic, and Clinical Research.Viruses · 2023Review
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Coronavirus Disease-2019 (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus. Various studies exist about the molecular mechanisms of viral infection. However, such information is spread across many publications and it is very time-consuming to integrate, and exploit. We develop CoVex, an interactive online platform for SARS-CoV-2 host interactome exploration and drug (target) identification. CoVex integrates virus-human protein interactions, human protein-protein interactions, and drug-target interactions. It allows visual exploration of the virus-host interactome and implements systems medicine algorithms for network-based prediction of drug candidates. Thus, CoVex is a resource to understand molecular mechanisms of pathogenicity and to prioritize candidate therapeutics. We investigate recent hypotheses on a systems biology level to explore mechanistic virus life cycle drivers, and to extract drug repurposing candidates. CoVex renders COVID-19 drug research systems-medicine-ready by giving the scientific community direct access to network medicine algorithms. It is available at https://exbio.wzw.tum.de/covex/.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.